$LENZ
LENZ Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023008764 Filed on March 20, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.623M $8.289M $32.85M
YoY Change -1.15% 7.16% 45.94%
% of Gross Profit
Research & Development $16.24M $18.46M $72.79M
YoY Change -10.97% 64.77% 91.89%
% of Gross Profit
Depreciation & Amortization $700.0K $682.0K $2.352M
YoY Change 75.0% 106.67% 236.0%
% of Gross Profit
Operating Expenses $26.45M $26.75M $105.6M
YoY Change 1.9% 41.24% 74.77%
Operating Profit -$26.45M -$105.6M
YoY Change 1.9% 74.77%
Interest Expense $2.590M
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.516M $2.152M $4.587M
YoY Change 1945.53% 21420.0% 19012.5%
Pretax Income -$23.93M -$24.60M -$101.1M
YoY Change -7.36% 29.95% 42.81%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$23.93M -$24.60M -$101.1M
YoY Change -7.36% 29.95% 42.8%
Net Earnings / Revenue
Basic Earnings Per Share -$0.43 -$1.84
Diluted Earnings Per Share -$0.43 -$0.44 -$1.84
COMMON SHARES
Basic Shares Outstanding 58.16M 58.15M 54.87M
Diluted Shares Outstanding 55.86M 54.87M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $264.1M $268.2M $268.2M
YoY Change -22.14% -28.85% -28.85%
Cash & Equivalents $69.81M $47.73M $47.73M
Short-Term Investments $194.3M $220.5M $220.5M
Other Short-Term Assets $6.211M $7.136M $7.136M
YoY Change 35.79% 49.92% 49.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $270.3M $275.4M $275.4M
YoY Change -21.37% -27.87% -27.87%
LONG-TERM ASSETS
Property, Plant & Equipment $33.07M $22.63M $28.21M
YoY Change 252.78% 247.78% 56.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $15.32M $15.32M
YoY Change -100.0%
Other Assets $889.0K $1.289M $3.005M
YoY Change 25.04% 183.92% 38.48%
Total Long-Term Assets $39.69M $46.54M $46.54M
YoY Change 13.89% 129.8% 129.8%
TOTAL ASSETS
Total Short-Term Assets $270.3M $275.4M $275.4M
Total Long-Term Assets $39.69M $46.54M $46.54M
Total Assets $310.0M $321.9M $321.9M
YoY Change -18.12% -19.92% -19.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.992M $2.608M $2.608M
YoY Change -35.09% 6.32% 6.32%
Accrued Expenses $12.35M $10.44M $10.44M
YoY Change 2369.8% 7.69% 7.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.34M $13.04M $13.04M
YoY Change 12.35% 7.41% 7.41%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $19.43M $10.82M $12.57M
YoY Change 327.81% 86.73% 116.91%
Total Long-Term Liabilities $19.43M $10.82M $12.57M
YoY Change 327.81% 86.73% 116.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.34M $13.04M $13.04M
Total Long-Term Liabilities $19.43M $10.82M $12.57M
Total Liabilities $33.77M $25.61M $25.61M
YoY Change 95.13% 42.78% 42.78%
SHAREHOLDERS EQUITY
Retained Earnings -$266.3M -$242.4M
YoY Change 59.27% 71.49%
Common Stock $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $276.2M $296.3M $296.3M
YoY Change
Total Liabilities & Shareholders Equity $310.0M $321.9M $321.9M
YoY Change -18.12% -19.92% -19.92%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$23.93M -$24.60M -$101.1M
YoY Change -7.36% 29.95% 42.8%
Depreciation, Depletion And Amortization $700.0K $682.0K $2.352M
YoY Change 75.0% 106.67% 236.0%
Cash From Operating Activities -$21.07M -$22.43M -$88.00M
YoY Change -0.78% 43.84% 66.35%
INVESTING ACTIVITIES
Capital Expenditures $383.0K $1.021M $6.594M
YoY Change -88.3% -204.08% 14.88%
Acquisitions
YoY Change
Other Investing Activities $43.55M $14.54M -$235.3M
YoY Change -126.01%
Cash From Investing Activities $43.16M $13.52M -$241.9M
YoY Change -125.29% -1478.59% 4113.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -8.000K 244.0K 597.0K
YoY Change -22.04% -99.86%
NET CHANGE
Cash From Operating Activities -21.07M -22.43M -88.00M
Cash From Investing Activities 43.16M 13.52M -241.9M
Cash From Financing Activities -8.000K 244.0K 597.0K
Net Change In Cash 22.08M -8.661M -329.2M
YoY Change -111.51% -46.74% -191.74%
FREE CASH FLOW
Cash From Operating Activities -$21.07M -$22.43M -$88.00M
Capital Expenditures $383.0K $1.021M $6.594M
Free Cash Flow -$21.46M -$23.45M -$94.59M
YoY Change -12.47% 60.48% 61.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001815776
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40532
CY2022 dei Entity Registrant Name
EntityRegistrantName
GRAPHITE BIO, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4867570
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Haskins Way
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 210
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
484-0886
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
CY2022 dei Trading Symbol
TradingSymbol
GRPH
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
150100000
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58163637
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47730000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376976000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
220499000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7136000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4760000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
275365000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
381736000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1716000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1716000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
15322000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22630000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6507000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5580000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11574000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1289000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
454000
CY2022Q4 us-gaap Assets
Assets
321902000
CY2021Q4 us-gaap Assets
Assets
401987000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2608000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2453000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3799000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2689000
CY2022Q4 grph Accrued Research Costs
AccruedResearchCosts
720000
CY2021Q4 grph Accrued Research Costs
AccruedResearchCosts
633000
CY2022Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1871000
CY2021Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
886000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4045000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5482000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13043000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12143000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1749000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5794000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10819000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Liabilities
Liabilities
25611000
CY2021Q4 us-gaap Liabilities
Liabilities
17937000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58221760
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58221760
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58010823
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58010823
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
539741000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
525400000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1048000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242403000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141351000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
296291000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
384050000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
321902000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
401987000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72787000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37932000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32852000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22511000
CY2022 us-gaap Operating Expenses
OperatingExpenses
105639000
CY2021 us-gaap Operating Expenses
OperatingExpenses
60443000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-105639000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-60443000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4587000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000
CY2022 grph Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
CY2021 grph Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
10341000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4587000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10317000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-101052000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-70760000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1048000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022 grph Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-102100000
CY2021 grph Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-70760000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54873675
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54873675
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919255
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919255
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-65408000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
306000
CY2021 grph Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
144000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7871000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-70760000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
384050000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
656000
CY2022 grph Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
131000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13534000
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1048000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-101052000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
296291000
CY2022 us-gaap Profit Loss
ProfitLoss
-101052000
CY2021 us-gaap Profit Loss
ProfitLoss
-70760000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1600000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2352000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
734000
CY2022 grph Non Cash Lease Expense
NonCashLeaseExpense
5994000
CY2021 grph Non Cash Lease Expense
NonCashLeaseExpense
1460000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
13534000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
7871000
CY2022 grph Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
CY2021 grph Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
10341000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3211000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3914000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
194000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1825000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1110000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2223000
CY2022 grph Increase Decrease In Accrued Research Costs
IncreaseDecreaseInAccruedResearchCosts
87000
CY2021 grph Increase Decrease In Accrued Research Costs
IncreaseDecreaseInAccruedResearchCosts
-1131000
CY2022 grph Increase Decrease In Accrued Expenses And Other Current Liabilities And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilitiesAndOtherLiabilities
94000
CY2021 grph Increase Decrease In Accrued Expenses And Other Current Liabilities And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilitiesAndOtherLiabilities
257000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5482000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1758000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87980000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52852000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6594000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5740000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
405519000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
170250000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-241863000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5740000
CY2022 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0
CY2021 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
165521000
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
251323000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
656000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
306000
CY2022 grph Proceeds From Issuance Of Common Stock Upon Early Exercises Of Stock Options
ProceedsFromIssuanceOfCommonStockUponEarlyExercisesOfStockOptions
0
CY2021 grph Proceeds From Issuance Of Common Stock Upon Early Exercises Of Stock Options
ProceedsFromIssuanceOfCommonStockUponEarlyExercisesOfStockOptions
289000
CY2022 grph Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
79000
CY2021 grph Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
597000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
417467000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-329246000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
358875000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
378692000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19817000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49446000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
378692000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47730000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376976000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1716000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1716000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49446000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
378692000
CY2022 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
260532000
CY2022 grph Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
-36000
CY2021 grph Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
-75000
CY2022 grph Settlement Of Redeemable Convertible Preferred Stock Tranche Liability
SettlementOfRedeemableConvertiblePreferredStockTrancheLiability
0
CY2021 grph Settlement Of Redeemable Convertible Preferred Stock Tranche Liability
SettlementOfRedeemableConvertiblePreferredStockTrancheLiability
-39403000
CY2022 grph Additions To Right Of Use Assets From New Operating Lease Liabilities
AdditionsToRightOfUseAssetsFromNewOperatingLeaseLiabilities
0
CY2021 grph Additions To Right Of Use Assets From New Operating Lease Liabilities
AdditionsToRightOfUseAssetsFromNewOperatingLeaseLiabilities
13034000
CY2022 grph Lessor Funded Lease Incentives Included In Property And Equipment
LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment
11920000
CY2021 grph Lessor Funded Lease Incentives Included In Property And Equipment
LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment
0
CY2022 grph Noncash Or Part Noncash Vesting Of Early Exercised Stock Options
NoncashOrPartNoncashVestingOfEarlyExercisedStockOptions
131000
CY2021 grph Noncash Or Part Noncash Vesting Of Early Exercised Stock Options
NoncashOrPartNoncashVestingOfEarlyExercisedStockOptions
144000
CY2022 grph Repurchase Of Unvested Early Exercised Shares Included In Accounts Payable
RepurchaseOfUnvestedEarlyExercisedSharesIncludedInAccountsPayable
17000
CY2021 grph Repurchase Of Unvested Early Exercised Shares Included In Accounts Payable
RepurchaseOfUnvestedEarlyExercisedSharesIncludedInAccountsPayable
42000
CY2021 grph Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Included In Accounts Receivable
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsIncludedInAccountsReceivable
14000
CY2022 grph Initial Public Offering Closed Date
InitialPublicOfferingClosedDate
2021-06-29
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-101100000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-88000000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242400000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
283600000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of the marketable securities, the fair value of redeemable convertible preferred stock and common stock, stock-based compensation expense, accruals for research and development costs, lease assets and liabilities, the valuation of deferred tax assets, and uncertain income tax positions. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with major financial institution and amounts may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institution in which the cash and cash equivalents are held. The Company has not experienced any losses on deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1700000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1700000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 grph Research And Development Credits To Offset Payroll Tax Expenses
ResearchAndDevelopmentCreditsToOffsetPayrollTaxExpenses
100000
CY2022 grph Research And Development Credit Generated Against Employer Portion Payroll Tax
ResearchAndDevelopmentCreditGeneratedAgainstEmployerPortionPayrollTax
300000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
236869000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1076000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
235821000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
220500000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
15300000
CY2022Q4 us-gaap Supplies
Supplies
2486000
CY2021Q4 us-gaap Supplies
Supplies
1834000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1343000
CY2022Q4 grph Share Based Compensation Arrangement By Share Based Payment Award Remaining Liability Related To Early Exercised Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingLiabilityRelatedToEarlyExercisedStockOptions
100000
CY2021Q4 grph Share Based Compensation Arrangement By Share Based Payment Award Remaining Liability Related To Early Exercised Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingLiabilityRelatedToEarlyExercisedStockOptions
300000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1543000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3307000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1383000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7136000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4760000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25837000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7362000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3207000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
855000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22630000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6507000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
367000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
186000
CY2022Q4 grph Accrued Early Exercise Liability
AccruedEarlyExerciseLiability
150000
CY2021Q4 grph Accrued Early Exercise Liability
AccruedEarlyExerciseLiability
337000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1354000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
363000
CY2022Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1871000
CY2021Q4 grph Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
886000
CY2022Q4 grph Accrued Termination And Cancellation Charges
AccruedTerminationAndCancellationCharges
0
CY2021Q4 grph Accrued Termination And Cancellation Charges
AccruedTerminationAndCancellationCharges
0
CY2022 grph Royalty Payment Due
RoyaltyPaymentDue
0
CY2021 grph Royalty Payment Due
RoyaltyPaymentDue
0
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4000000.0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1700000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P19M
CY2022Q4 grph Lessee Operating Lease Weighted Average Incremental Borrowing Rate
LesseeOperatingLeaseWeightedAverageIncrementalBorrowingRate
0.085
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P1Y
CY2022 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The original term of the lease was from May 11, 2020 to June 30, 2021 with an option to renew. In March 2021, the Company entered into an amendment to the lease agreement and extended the term of the lease to September 30, 2021.
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4331000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1468000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
375000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6174000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
380000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5794000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
6700000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
1300000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
200000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
6172000
CY2021Q2 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
260500000
CY2020Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
10000000
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.00
CY2020Q2 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
10000000.0
CY2020Q2 grph Preferred Stock Additional Shares Issued
PreferredStockAdditionalSharesIssued
30000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q4 grph Share Based Compensation Arrangement By Share Based Payment Award Remained Subject To Right Of Repurchase Of Early Exercised Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainedSubjectToRightOfRepurchaseOfEarlyExercisedStockOptions
554695
CY2021Q4 grph Share Based Compensation Arrangement By Share Based Payment Award Remained Subject To Right Of Repurchase Of Early Exercised Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainedSubjectToRightOfRepurchaseOfEarlyExercisedStockOptions
1195631
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13893161
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10034853
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The shares of the Company’s common stock issued to its founders for their services as an employee, advisor, or consultant vest monthly over four years with one year cliff from the vesting commencement date.
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022 grph Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
CY2020Q2 grph Aggregate Common Stock Vested
AggregateCommonStockVested
912212
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
7273848
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
564000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.21
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5000000.0
CY2022 grph Early Exercise Of Stock Options Repurchase Right Lapse Period
EarlyExerciseOfStockOptionsRepurchaseRightLapsePeriod
P180D
CY2022 grph Stock Issued During Period Shares Stock Options Exercised And Repurchased
StockIssuedDuringPeriodSharesStockOptionsExercisedAndRepurchased
189414
CY2021 grph Stock Issued During Period Shares Stock Options Exercised And Repurchased
StockIssuedDuringPeriodSharesStockOptionsExercisedAndRepurchased
138596
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13534000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7871000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13534000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7871000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-101052000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-70760000
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
58111437
CY2021 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
35121114
CY2022 grph Weighted Average Unvested Restricted Shares And Shares Subject To Repurchase Or Cancellation
WeightedAverageUnvestedRestrictedSharesAndSharesSubjectToRepurchaseOrCancellation
3237762
CY2021 grph Weighted Average Unvested Restricted Shares And Shares Subject To Repurchase Or Cancellation
WeightedAverageUnvestedRestrictedSharesAndSharesSubjectToRepurchaseOrCancellation
6201859
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54873675
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54873675
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919255
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919255
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10690909000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9930793000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0110
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0194
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0069
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0026
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0111
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0101
CY2022 grph Effective Income Tax Rate Reconciliation Cancellation Of Debt Income
EffectiveIncomeTaxRateReconciliationCancellationOfDebtIncome
0
CY2021 grph Effective Income Tax Rate Reconciliation Cancellation Of Debt Income
EffectiveIncomeTaxRateReconciliationCancellationOfDebtIncome
0
CY2022 grph Effective Income Tax Rate Reconciliation Tranche Liability
EffectiveIncomeTaxRateReconciliationTrancheLiability
0
CY2021 grph Effective Income Tax Rate Reconciliation Tranche Liability
EffectiveIncomeTaxRateReconciliationTrancheLiability
0.0306
CY2022 grph Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0
CY2021 grph Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0097
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0096
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2155
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1967
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15940000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12006000
CY2022Q4 grph Deferred Tax Assets Tax Credit Carryforwards Capitalized Research And Development Costs
DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopmentCosts
13815000
CY2021Q4 grph Deferred Tax Assets Tax Credit Carryforwards Capitalized Research And Development Costs
DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopmentCosts
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
5699000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
2682000
CY2022Q4 grph Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
1220000
CY2021Q4 grph Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
2368000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1703000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
784000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
735000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
525000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
170000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
396000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
39285000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18763000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38110000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16332000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1175000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2431000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1175000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
2431000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1175000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2431000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16332000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2414000
CY2022 grph Valuation Allowance Increases Recorded To Income Tax Provision
ValuationAllowanceIncreasesRecordedToIncomeTaxProvision
21778000
CY2021 grph Valuation Allowance Increases Recorded To Income Tax Provision
ValuationAllowanceIncreasesRecordedToIncomeTaxProvision
13918000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38110000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16332000
CY2021 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
The Company’s U.S. federal and state income tax returns are generally subject to tax examinations for the tax years from inception through December 31, 2021. There are currently no pending income tax examinations. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax authorities to the extent utilized in a future period.
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1407000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1862000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1258000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
568000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
149000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2701000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1407000
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2022 dei Auditor Location
AuditorLocation
San Francisco, CA
CY2022 dei Auditor Firm
AuditorFirmId
34

Files In Submission

Name View Source Status
0000950170-23-008764-index-headers.html Edgar Link pending
0000950170-23-008764-index.html Edgar Link pending
0000950170-23-008764.txt Edgar Link pending
0000950170-23-008764-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
grph-20221231.htm Edgar Link pending
grph-20221231.xsd Edgar Link pending
grph-ex10_24.htm Edgar Link pending
grph-ex21_1.htm Edgar Link pending
grph-ex23_1.htm Edgar Link pending
grph-ex31_1.htm Edgar Link pending
grph-ex31_2.htm Edgar Link pending
grph-ex32_1.htm Edgar Link pending
grph-ex32_2.htm Edgar Link pending
img51297447_0.jpg Edgar Link pending
img51297447_1.jpg Edgar Link pending
img51297447_10.jpg Edgar Link pending
img51297447_11.jpg Edgar Link pending
img51297447_12.jpg Edgar Link pending
img51297447_13.jpg Edgar Link pending
img51297447_14.jpg Edgar Link pending
img51297447_15.jpg Edgar Link pending
img51297447_16.jpg Edgar Link pending
img51297447_17.jpg Edgar Link pending
img51297447_18.jpg Edgar Link pending
img51297447_19.jpg Edgar Link pending
img51297447_2.jpg Edgar Link pending
img51297447_20.jpg Edgar Link pending
img51297447_21.jpg Edgar Link pending
img51297447_22.jpg Edgar Link pending
img51297447_3.jpg Edgar Link pending
img51297447_4.jpg Edgar Link pending
img51297447_5.jpg Edgar Link pending
img51297447_6.jpg Edgar Link pending
img51297447_7.jpg Edgar Link pending
img51297447_8.jpg Edgar Link pending
img51297447_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
grph-20221231_def.xml Edgar Link unprocessable
grph-20221231_lab.xml Edgar Link unprocessable
grph-20221231_pre.xml Edgar Link unprocessable
grph-20221231_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
grph-20221231_cal.xml Edgar Link unprocessable